key: cord-0944869-uuqjkyom
authors: Ranjbar, Mitra; Karbalaie Niya, Mohammad Hadi; Roham, Maryam; Rezaie, Nader; Yadollahzadeh, Mahdi; Farrokhpour, Mohsen; Azimi, Mehdi; Motamed, Nima; Perumal, Dhayaneethie; Tameshkel, Fahimeh Safarnezhad; Dadras, Farahnaz; Madani, Nahid Hashemi; Ghanbari, Behrooz; Faraji, Amirhossein; Nikkhah, Mehdi; Rahmani, Shahrzad; Golgiri, Fatemah; Emadi, Seyed Yadollah; Abbasi, Rowshanak; Mohseni, Iman; Babaei, Mohammad Reza; Eskandari, Ramin; Ataee, Manizhe; Panahi, Mahshid; Zamani, Farhad; Makiani, Mahin Jamshidi; Laali, Azadeh
title: Serum level of Vitamin D is associated with COVID-19 mortality rate in hospitalized patients
date: 2021-11-29
journal: J Res Med Sci
DOI: 10.4103/jrms.jrms_1151_20
sha: 435ebb6ba2b12d8dc06111d362611f2c4ffe72f9
doc_id: 944869
cord_uid: uuqjkyom

BACKGROUND: Due to widespread of coronavirus disease 2019 (COVID-19) infection, identification of its risk factors and clinical characteristics are important. The aim of the present study was to assess Vitamin D levels in individuals with severe acute respiratory syndrome coronavirus-19 infection and to report on its potential as a predictive marker. MATERIALS AND METHODS: All patients, diagnosed with COVID-19 infection from February 16 to March 21, 2020, and referred to Firoozgar Hospital, Tehran, Iran, were enrolled in this study. Vitamin D analysis was undertaken on patient serum samples using a commercial kit (Pars Azmoon Co., Tehran, Iran). SPSS v. 22 was used for statistical analysis. RESULTS: Vitamin D serum concentration was analyzed in a total of 317 patients whose mean age ± standard deviation was 62.05 ± 15 years and with 62.5% being male. A significant association of Vitamin D level and death was observed. Higher levels of serum Vitamin D had protection against death (odds ratio = 0.955 [95% confidence interval = 0.923–0.988], P = 0.008). CONCLUSION: As a preliminary study in the Iranian population who suffered COVID-19 disease, we identified that Vitamin D deficiency was associated with a higher death rate and intensive care unit admission.

Novel coronavirus disease 2019 (COVID-19) is currently a worldwide health concern that causes mild upper respiratory tract infection (URTI) to severe lower respiratory tract infection (LRTI) and severe acute respiratory syndrome (SARS). Its outbreak began on their impact on society to guide and inform solutions and countermeasures. Early evidence suggests older age and the presence of underlying comorbidities such as cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and cancer, [1] smoking, obesity, [2] and male gender, [3] predisposes individuals to infection and an increased risk of death. It is now known that the virus inflicts harm irrespective of age or health status. It is therefore important to fully identify genetic, psychological, environmental, and biological risk factors that may influence the course and severity of the disease. [4] Deficiencies in minerals and vitamins have been reported to be a predisposing factor in a variety of diseases. [5] Vitamin D, in particular, has been studied for decades with a more recent emphasis on its role, in deficient states, in cancers, neuropsychiatric disorders, autoimmune diseases, [5] and chronic conditions such as bone metabolic disorders, cardiovascular disease, chronic respiratory tract infections (RTIs), diabetes mellitus, hypertension and in viral infections. [6] High serum levels of 25-hydroxyvitamin D [25 (OH) D] have been associated with reduced risk of dengue, hepatitis, herpesvirus, hepatitis B and C viruses, human immunodeficiency virus, influenza, respiratory syncytial virus infections, and pneumonia. [6] The exact mechanisms of the interplay between Vitamin D and viral disease development are not fully poorly understood but are thought to involve the induction of an anti-viral state, functional immunoregulatory features, interaction with cellular and viral factors, induction of autophagy and apoptosis, and genetic and epigenetic alterations. [7] Now, with the emergence and rapid spread of COVID-19, the influence of Vitamin D status in infected individuals on the clinical outcomes is an area of interest. COVID-19 incidence has first ranked between others in Iran as an Eastern Mediterranean Region countries. [8] The incidence rate, severity, and death risk of influenza, pneumonia, and the current COVID-19 may reduce by optimal levels of 25-hydroxyvitamin D. [6] As Vitamin D suboptimal levels in Iranian general population was reported in over 70%. [9] The present study was aimed to evaluate the COVID-19 suffered patients 25(OH)D serum concentration which is not reported yet.

This cross-sectional study was performed in Firoozgar Hospital, Tehran, an affiliate to Iran University of Medical Sciences, Tehran in Iran. The hospital served as a referral center of COVID-19 patients. All patients admitted to the hospital, from January 16 to March 21, 2020, were enrolled in the study by expert specialists using the standard protocol of WHO interim guidance for COVID-19 diagnosis. Informed consent was obtained from patients who, if in agreement to participate, signed consent form.

Inclusion criteria were the presence of signs and symptoms of respiratory infection in addition to at least a chest computed tomographic (CT) scan or X-ray and an RT-PCR positive for COVID-19. Patients who had not undergone a Vitamin D assessment were excluded from the study.

The medical records of recruited patients were collated by the research team of the Department of Gastrointestinal and Liver Disease Research Center at the Iran University of Medical Sciences. Some demographic, clinical, and laboratory data of recruited patients were reviewed to find the eligible ones (not shown). We included some clinical and laboratory data [ Table 1 ]. The clinical outcomes (i.e., length of hospital stay, discharges, and mortality) were monitored up to the end date of the study, March 21, 2020. The study ethics approval was obtained from Iran University of Medical Sciences, Tehran, Iran (code IR.IUMS.REC.1399.012).

Venous blood samples were obtained from each participant at the time of the Hospital admission. Serum separator tube used for blood clotting and sera obtained after centrifugation. An Auto-Analyzer BS200 (Mindray, Shenzhen, China) used for serum 25-hydroxycholecalciferol (25-OH Vitamin D) assessment by commercial diagnostic kits from Pars Azmoon Company (Pars Azmoon Co., Tehran, Iran). The serum 25(OH)D concentration cut-off clustered based on values >30 ng/ml considered as sufficient, 21-29 ng/ml as insufficient, and ≤20 ng/ml as deficient.

COVID-19 one-step Reverse Transcription Real-time Polymerase Chain Reaction (RT-PCR) (CAPITAL™ qRT-PCR Probe Mix, biotechrabbit, GmbH, Germany) 

The study population involved a total of 317 hospitalized COVID-19 positive patients. Of these 12% (38) Table 1 ].

The mean age of survivors and nonsurvivors was 6 0 . 4 9 ± 1 5 . 6 3 ye a r s a n d 7 2 . 1 2 ± 1 2 . 8 7 ye a r s respectively (P < 0.001). The mean length of stay in hospital for survivors and nonsurvivors was 3.83 ± 3.39 days, and 3.69 ± 3.06 days respectively (P < 0.001). Table 2 shows the frequency distribution of sex, age group, ICU admission status, and hospital length of stay in patients with COVID-19, according to mortality outcome A significant association was observed between mortality outcome and patient age groups (P = 0.002) as well as ICU admission (P < 0.001). Tables 3 and 4 show the mean and distribution frequency of Vitamin D level based on ICU admission status, hospital length of stay, and death. Based on our results, the vitamin level in nonsurvivors was significantly lower than survivors (P = 0.005) more details are presented in Tables 3 and 4 . Table 5 shows the results of multiple logistic regression analysis in which death was considered the related outcome and sex, age, length of stay, ICU admission, and Vitamin D serum level were considered the potential predictors. Age, admission in ICU, and Vitamin D serum level showed a significant association with mortality. A higher level of serum Vitamin D showed significant protection in survival outcome (odds ratio = 0.955 [95% confidence interval = 0.923-0.988)]).

We evaluated the association between Vitamin D levels in patients with COVID-19 disease and related outcomes including, the need for hospitalization in ICU and mortality rate. Our study showed a significant independent association between Vitamin D level and mortality rate in these groups of patients, in that, a lower serum Vitamin D was linked to a higher mortality rate in patients with COVID-19. There was a significant association between Vitamin D level and the ICU admission.

We know the most important cause of death in people with COVID-19 is respiratory involvement. [6, 7] On the other hand, the previous studies have reported on an association between respiratory diseases [10] [11] [12] and a lower level of serum Vitamin D Chen et al. proposed several mechanisms at the molecular level [10] in the relationship between Vitamin D and pathological respiratory distress. Jolliffe et al. reported a broad and consistent relationship between lower levels of Vitamin D and a higher susceptibility to acute respiratory infection in a systemic review, although, the authors were unable to conclude that Vitamin D supplementation has a protective effect against acute respiratory infection. [11] However, Martineau et al. concluded that Vitamin D supplementation was safe and effective against acute RTI, particularly in patients with severe Vitamin D deficiency. [12] In another systematic review and meta-analysis, Pham et al. showed that Vitamin D plays a critical role against acute RTI risk and its severity, particularly in individuals with Vitamin D deficiency. [13] It is worth noting that previous studies proposed that the Vitamin D has an important immunomodulatory role in the optimal function of the immune system. [8, 9] The steroid hormone may act against related pathogens and reduce the inflammatory responses. [14] [15] [16] Vitamin D has a role in the production of some antimicrobial peptides such as defensins and cathelicidin and thus can play a role against microbiological pathogens. [17] Journal of Research in Medical Sciences | 2021 | 4 Recent studies show that the mortality rate in people with COVID-19 occurs at a higher rate in older patients. [1] Kim et al. demonstrated an association of low serum level of Vitamin D with frailty in elderly people. [18] On the other hand, frailty was considered as a strong predictor of mortality rate in older patients. [19] This association was independent of gender, age, other morbidities, and even functional status of involved older adults. [19] As a result, frailty can be considered as an important mediator between lower levels of Vitamin D and higher mortality rate in older patients. On the other hand, the recent studies showed the cardiovascular comorbidities are common findings in patients with COVID-19, where myocardial injury occurs in more than 25% of acute ill patients, and also it is related to a higher risk of death in involved patients. [20] This injury may occur in two patterns, including acute myocardial injury and injury due to illness intensification. [20] Our study showed that a lower level of serum level of Vitamin D is associated with a higher mortality rate in patients with COVID-19 independent of age and sex. This preliminary study, to the best knowledge of the authors, is the first to evaluate the association between serum level of Vitamin D and mortality rate in patients with COVID-19 disease. We suggest that the role of Vitamin D in SARS-Cov-2 infection be fully explored in infection and at all stages of disease in well-designed clinical studies.

Our study had some limitations. We evaluated the association between serum baseline Vitamin D level and mortality rate in an observational study. Consequently, we were not able to determine whether Vitamin D deficiency could be considered a factor in increasing patient mortality or whether the severity of the disease had significantly reduced Vitamin D levels in those who succumbed.

Although we adjusted the related results based on age and sex, some other confounding variables such as underlying diseases were not included. However, the inclusion of ICU admission and hospital length of stay in logistic regression models can help moderate some of the potentially influential variables on the need for hospitalization that are also 

Lower Vitamin D level was significantly associated with the mortality rate of patients confirmed with COVID-19, independent of age and sex. 

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Clinical Findings of Patients with Coronavirus Disease

Coronavirus disease 2019 (COVID-19) in Italy

Real-time estimation of the risk of death from novel coronavirus (COVID-19) infection: Inference using exported cases

Vitamin D and chronic diseases

Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

The interplay between vitamin D and viral infections

Coronavirus disease (COVID-2019) situation reports

The optimal vitamin D cut-off value associated with hyperglycemia in an Iranian population

Effect of early vitamin D supplementation on asthma and the possible mechanisms

Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Acute respiratory tract infection and 25-hydroxyvitamin d concentration: A ystematic review and meta-analysis

Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro

Vitamin D modulation of innate immune responses to respiratory viral infections

Vitamin D deficiency promotes epithelial barrier dysfunction and intestinal inflammation

Vitamin D, innate immunity and upper respiratory tract infection

Association of serum vitamin D with frailty in older Korean adults

Frailty as a predictor of mortality in older adults within 5 years of psychiatric admission

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

Acknowledgments This study was done as a grant in Iran University of Medical Sciences, Tehran, Iran (No: 98-5-41-17553).

Nil.

There are no conflicts of interest.